Abstract: The vaccine induced durable antibodies that potently neutralized prototypic strain and B.1.1.7 lineage variant pseudoviruses containing N501Y or D614G mutations alone or in combination with a N439K mutation (B.1.258 lineage), with a L452R mutation (B.1.427 or B.1.429 lineage), or a L452R-E484Q double mutation (B.1.617.1 variant), although neutralizing activity against B.1.1.7 lineage variant containing 10 amino acid changes in the S protein was slightly reduced.
The twin-beginnings of COVID-19 in Asia and Europe-one prevails quickly.
Abstract: The first wave is a group of four mutations (C241T, C3037T, C14408T and A23403G [this being the amino acid change D614G]; all designated 0 to 1 below).
Abstract: This DG (D614G) group, fixed at the start of the pandemic, is the foundation of all subsequent waves of strains.
Whole genome sequencing of SARS-CoV2 strains circulating in Iran during five waves of pandemic.
Abstract: There were different mutations in all parts of the genomes but Spike-D614G, NSP12-P323L, N-R203K and N-G204R were the most frequent mutants in these studied viruses.
Delta variant (B.1.617.2) of SARS-CoV-2: Mutations, impact, challenges and possible solutions.
PMID: 35507895
2022
Human vaccines & immunotherapeutics
Abstract: The enhanced transmissibility of Delta variant has been associated with critical mutations such as D614G, L452R, P681R, and T478K in the S-protein.
Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies.
Result: A significant decrease in neutralization antibody titer was detected with the alpha and gamma variants relative to D614G variant among the three age ranges (Figure 1B).
Result: Although no significant decrease was detected, the GMT of the neutraliz
Figure: GMTs and 95% CIs are indicated: D614G (75.1), alpha (18.5), gamma (10.05) variant.
Figure: Neutralization assays with D614G (lineage B, blue circles), alpha (lineage B.1.1.7, red circles) and gamma (lineage P.1, green circles) variants were done.
Figure: Neutralization assays with infectious D614G (lineage B), alpha (lineage B.1.1.7) and gamma (lineage P.1) variants were done.
Figure: Patterns of neutralizing antibody titers of 44 CoronaVac-vaccinated human sera against infectious D614G, alpha and gamma SARS-CoV-2 variants.
Assessment of the binding interactions of SARS-CoV-2 spike glycoprotein variants.
PMID: 34545316
2022
Journal of pharmaceutical analysis
Result: Such finding is consistent with that of recent studies where the increased infectivity of viruses with the D614G mutation was not found to be explained by a greater ACE2 binding activity.
Result: The D614G and N501Y mutant RBD/S1 proteins displayed distinct kinetic profiles.
Result: The kon of mutant D614G to ACE2 was 4.8-fold slower than that of the original RBD, whereas the koff was 0.5-fold faster, resulting in a 10-fold decrease in the binding affinity.
Result: The low similarity score (21.1%) of D614G relative to the original RBD, compared to the other mutants, also highlighted the impact of the mutation relative to the binding interaction.
Result: The sensorgrams overla
Analyzing the effect of mutations in SARS-CoV2 papain-like protease from Saudi isolates on protein structure and drug-protein binding: Molecular modelling and dynamics studies.
PMID: 34548835
2022
Saudi journal of biological sciences
Introduction: Some of these mutations have relatively high incidences, such as a non-synonymous mutation (D614G) in the virus's S protein.
Discussion: Furthermore, D614G, due to the higher flexibility, gains an increase in its thermostability as compared to the WT virus.
Discussion: This is of substantial importance because earlier reports show that spike protein substitution to glycine in D614G mutation increases the flexibility due to the shorter side chain allowing a more efficient cleavage of S protein subunits, which might explain the improved ACE binding affinity.
Proteolytic activation of SARS-CoV-2 spike protein.
Introduction: All of these VOCs have the D614G mutation (Figure 5).
Introduction: As mentioned earlier, SARS-CoV-2 with the D614G mutation, which emerged early in the epidemic and has become a major cause of the global pandemic, has gained increased infectivity because of the D614G mutation.
Introduction: Besides, the 614th amino acid is located in the vicinity of the S1/S2 cleavage site (Figure 7), and the D614G mutation increases S1/S2 cleavability by furin (Figure 5).
Introduction: In fact, the D614G mutation is of great significance when the S protein contains an FCM.
Introduction: Nevertheless, given the effect of the Figure: Alteration of interprotomer interaction by D614G mutation.
BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus.
PMID: 34607791
2022
Annals of the rheumatic diseases
Result: Among patients with neutralising antibody activity against D614G strain, 100% (37/37) of patients also efficiently neutralised B.1.1.7 strain, 89% (33/37) B.1.617.1 variant, 92% (34/37) B.1.617.2 variant, 87% (32/37) B.1.1.28 variant, 89% (33/37) B.1.1.28 variant and 60% of patients (27/37) had detectable neutralising activity against B.1.351.
Result: As expected, we confirm a strong correlation between anti-RBD antibody levels and neutralisation titres (SARS-CoV-2 D614G r=0.82, p<0.0001; figure 3A).
Result: Consistent with previous studies, we found that vaccine-induced IgG antibodies efficiently cross-neutralise variants B.1.1.7 (ID50 median (min-max); D614G 1453 (30-18 910) and B.1.1.7 514.5 (30-12 625), ns; figure 3E).
Result: Interestingly, SARS-CoV-2-specific T cell responses were nevertheless detected in two out of six p
The Ethics of Human Challenge Trials Using Emerging Severe Acute Respiratory Syndrome 2 Variants.
PMID: 34624095
2022
The Journal of infectious diseases
Abstract: The world's first coronavirus disease 2019 human challenge trial using the D614G strain of severe acute respiratory syndrome 2 (SARS-CoV-2) is underway in the United Kingdom.
SARS_CoV_2 mutation literature information.
PMID: 
2022
Translational research
Browser Board
Co-occurred Entities
Filtrator
ViMRT